Shares of Dechra Pharmaceuticals plc (LON:DPH) have been assigned an average rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is GBX 1,733.50 ($22.32).

Several equities research analysts recently commented on DPH shares. N+1 Singer reissued a “buy” rating and set a GBX 1,666 ($21.45) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday. Numis Securities Ltd reissued an “add” rating and set a GBX 1,890 ($24.33) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday. Investec reissued a “buy” rating and set a GBX 1,840 ($23.69) price objective on shares of Dechra Pharmaceuticals plc in a research note on Thursday. Stifel Nicolaus boosted their price objective on shares of Dechra Pharmaceuticals plc from GBX 1,440 ($18.54) to GBX 1,550 ($19.96) and gave the stock a “hold” rating in a research note on Tuesday, April 4th. Finally, Royal Bank of Canada boosted their price objective on shares of Dechra Pharmaceuticals plc from GBX 1,630 ($20.99) to GBX 1,890 ($24.33) and gave the stock an “outperform” rating in a research note on Tuesday, March 14th.

COPYRIGHT VIOLATION NOTICE: “Dechra Pharmaceuticals plc (DPH) Receives Average Rating of “Buy” from Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/10/dechra-pharmaceuticals-plc-dph-receives-average-rating-of-buy-from-brokerages.html.

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded down 1.81% during mid-day trading on Monday, reaching GBX 1682.00. 118,660 shares of the company’s stock were exchanged. The company has a 50 day moving average price of GBX 1,840.42 and a 200-day moving average price of GBX 1,620.69. The stock’s market cap is GBX 1.56 billion. Dechra Pharmaceuticals plc has a one year low of GBX 1,151.00 and a one year high of GBX 1,970.00.

In related news, insider Ian Page sold 134,500 shares of the business’s stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of GBX 1,927 ($24.81), for a total transaction of £2,591,815 ($3,336,957.64).

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals plc (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.